Bright Minds Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG research report →
Range $37 – $150
Price Chart
About the company
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DRUG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $201.23M
- P/E
- -9.97
- PEG
- 0.13
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- 0.57
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -12.56%
- ROIC
- -12.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,937,584
- Net Income
- $-12,229,348-336.5%
- EPS
- $-1.78-173.8%
- OCF Growth
- -369.8%
- FCF Growth
- -369.8%
- 52W High
- $123.75
- 52W Low
- $17.40
- 50D MA
- $44.51
- 200D MA
- $68.72
- Beta
- 0.09
- RSI (14)
- 27
- Avg Volume
- 173.24K
No earnings-call transcripts are available for DRUG yet.
- Free Float
- 73.9%
- Shares Outstanding
- 9.86M
- Float Shares
- 7.29M
of shares held by institutions
102 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 1.35M | ▲ 1.35M |
| Jupiter Topco LLC | 1.35M | ▲ 1.35M |
| Cormorant Asset Management, LP | 800.00K | ▼ 100.00K |
| Blackrock, Inc. | 651.79K | ▼ 34.39K |
| Vestal Point Capital, LP | 545.00K | 0 |
| Braidwell LP | 483.82K | 0 |
| Driehaus Capital Management LLC | 445.22K | ▲ 11.84K |
| Vivo Capital, LLC | 417.88K | ▼ 139.29K |
| Point72 Asset Management, L.P. | 372.48K | ▲ 45.06K |
| Adage Capital Partners Gp, L.L.C. | 324.80K | ▼ 10.20K |
| Balyasny Asset Management L.P. | 304.56K | ▼ 40.49K |
| Ra Capital Management, L.P. | 265.00K | 0 |
Held by 46 ETFs
Biggest fund positions in DRUG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Cormorant Asset Management, LP | sell | 109,331 |
| Nov 4, 24 | Cormorant Asset Management, LP | buy | 184,331 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 3,107 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 7,150 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 39,743 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 4,609 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 19,169 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,700 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,600 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 8,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRUG coverage
Recent articles, reports, and earnings notes.
No research on DRUG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRUG report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bright Minds Bioscience Inc. - DRUG
prnewswire.com · Nov 19
Bright Minds Biosciences Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your DRUG Investments
newsfilecorp.com · Nov 18
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bright Minds Bioscience Inc. - DRUG
globenewswire.com · Nov 17
DRUG CRACKDOWN: US deploys drones to combat traffickers at border
youtube.com · Nov 16
BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 52.3% Share Drop
businesswire.com · Nov 11
Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Nov 9
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Bright Minds Biosciences (DRUG)
globenewswire.com · Nov 5
Bright Minds Biosciences: Promising Catalysts Despite The FDA Setback
seekingalpha.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.